Form 4: Recursion Pharma Director Acquires Shares

Recursion Pharmaceuticals director Zavain Dar acquired 3,571 shares of Class A Common Stock as part of the company's director compensation policy.

Summary

• Zavain Dar, a Director of RECURSION PHARMACEUTICALS, INC. (RXRX), acquired 3,571 shares of Class A Common Stock.
• The transaction occurred on January 2, 2026.
• The shares were acquired at a price of $0, indicating they were issued as compensation.
• This acquisition was made pursuant to the Issuer's Outside Director Compensation Policy.
• Following this transaction, Dar Zavain directly beneficially owns 142,329 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director is increasing their stake, which can be interpreted as a vote of confidence in the company. However, it's a routine compensation event, not an open market purchase, limiting the strength of the positive signal.

Positives

• A director increasing their ownership stake, even through compensation, can signal confidence in the company's future prospects.
• The transaction aligns the director's interests more closely with those of the shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Director compensation, often including equity awards, is a standard practice across industries, including the biotechnology and pharmaceutical sectors, to attract and retain qualified board members and align their incentives with long-term company performance.

Comparison to Industry Standards

• The issuance of equity as part of an outside director compensation policy is a common practice among publicly traded companies, including those in the biotechnology sector, such as Moderna (MRNA) or BioNTech (BNTX), which frequently use stock awards to compensate their non-employee directors.
• The $0 price for the acquired shares is typical for stock grants or awards under a compensation plan, rather than an open market purchase.

Corporate Governance

Related Party Transactions

• The acquisition of 3,571 shares by Director Zavain Dar at a $0 price, pursuant to the company's Outside Director Compensation Policy, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's increased ownership as a positive signal of alignment and confidence in the company's future.
• Employees: No direct impact mentioned, but consistent application of compensation policies can contribute to overall corporate stability.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Director Compensation, Stock Acquisition, Zavain Dar, Biotechnology, Pharmaceuticals